Glenmark Receives FDA Approval to Market Generic Montelukast in the US

Glenmark Pharmaceuticals revealed that it will be marketing generic Montelukast Sodium tablets in the United States from August next year

Glenmark Pharmaceuticals revealed that it will be marketing generic Montelukast Sodium tablets in the United States from August next year after it received approval by the US Food and Drug Administration to provide the drugs for treating asthma and seasonal allergies.

Glenmark said that it will be manufacturing the tablets after Merck’s patent expires in August next year.

Asthma - Factors, Common Allergens, Diagnosis, Treatment, Support Groups, FAQs
It's a lung condition characterized by inflammation of the bronchi and constriction of the airways that result in coughing, wheezing or breathlessness. Allergy and other airway irritants can trigger it

The tablets are generic version of the Singulair tablets being sold by Merck with the 10mg strength tablets generating more than $3.2 billion in sales in the last 12 months.

The company also said that it has 73 products available in the US market. Furthermore, it also has over 40 abbreviated new drug applications (ANDAs) that have been submitted to the FDA for approval.

Source-Medindia

Allergy - Causes - Symptoms - Diagnosis - Treatment - FAQs - Videos
An allergy is a hypersensitive disorder of immune system. Substances that often cause allergic reactions are pollen, dust mites, mold spores, pet dander, food, insect stings and medicines.